

## **Supplementary Material**

- Article Title: Detection of Subclinical Depression in Bipolar Disorder: A Cross-Sectional, 4-Month Prospective Follow-Up Study at Community Mental Health Services (SIN-DEPRES)
- Author(s): Eduard Vieta, MD, PhD; Rosario de Arce, MD; Miguel A. Jiménez-Arriero, MD; Alfonso Rodriguez, MD, PhD; Vicent Balanzá, PhD, MD; and Silvia Cobaleda, MD; for the SIN-DEPRES Group
- **DOI Number:** 10.4088/JCP.09m05177

## List of Supplementary Material for the article

1. <u>eTable 1</u> Evolution of Depressive Symptoms According to Pharmacological Therapeutic Strategy

## **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eTable 1. Evolution of depressive symptoms according to pharmacological therapeutic strategy

Therapeutic strategy <sup>b</sup>	n 88	Clinical Stability for Depressive Symptoms <sup>a</sup>			Variation on MADRS Scale between Baseline and Final Assessments			
		n 82	% 93.2	<i>CI 95%</i> 85.9-96.8	<b>Mean</b> 0.2	<b>SD</b> 3.6	CI 95%	
							-0.61	0.93
Anticonvulsivant agent	90	78	86.7	86.7-92.2	0.7	5.9	-0.54	1.91
Lithium + Anticonvulsivant agent	82	73	89.0	80.4-94.1	0.2	5.9	-1.11	1.43
Lithium + Antipsychotic agent	98	86	87.8	79.8-92.9	0.0	5.2	-1.04	1.04
Lithium + Anticonvulsivant + Antipsychotic	118	97	82.2	74.3-88.1	1.5	6.2	0.31	2.55
Total <sup>c</sup>	476							

CI, Confidence Interval

<sup>a</sup> Stability on depressive symptoms has been considered as being when a patient had not suffered considerable increases in the MADRS scale between study visits, defined as increases above 50% from the baseline score, and the score at the final visit in this scale was not higher than 7.

<sup>b</sup> The pharmacological therapeutic strategies defined are mutually excluding groups and all groups exclude the use of antidepressant agents.

<sup>c</sup> Other patients were under therapeutic strategies different from those defined for this analysis.

The studied BD patients were in maintenance therapy, registering a mean of 2.8 drugs per patient. Among the psychotropic agents prescribed, the most common were lithium carbonate (n = 442, 59.8%), followed by lamotrigine (n = 247, 33.4%), olanzapine (n = 176, 23.8%) and valproic acid (n = 146, 19.8%). Compliance with the maintenance therapy, according investigator's opinion, indicated that 83.6% of cases had good compliance (n = 618), while a 15% misses doses during a standard week (n = 111). A 70,1% of patients was satisfied with the maintenance

treatment.